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Abstract 
Objective: In this 7-day pilot study we randomized healthy, normal-weight men and women to either a dietary inter-
vention with methionine and cysteine restriction enriched in PUFA (Met/Cyslow + PUFA, n = 7) or with high contents 
of methionine, cysteine and SFA (Met/Cyshigh + SFA, n = 7). The objective was to describe the short-term responses in 
oral glucose tolerance, amino acid profile, total fatty acid profile, pyruvate and lactate following a Met/Cyslow + PUFA 
diet vs. Met/Cyshigh + SFA.
Results: The diet groups consisted of five women and two men, aged 20–38 years. After the 7-d intervention median 
pre- and post-oral glucose tolerance test (OGTT) glucose concentrations were 5 mmol/L and 4 mmol/L respectively 
in the Met/Cyslow + PUFA group. In the Met/Cyshigh + SFA group, median pre- and post-OGTT glucose concentrations 
were 4.8 mmol/L and 4.65 mmol/L after the 7-d intervention. The responses in the amino acid profiles were similar 
in both groups during the intervention with the exception of serine. Fatty acids decreased from baseline to day 7 in 
both groups. Plasma lactate and pyruvate were similar for both groups with an increase to day 3 before approaching 
baseline values at day 7.
Trial registration: ClinicalTrials.gov: NCT02647970, registration date: January  6th 2016.
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Introduction
Methionine and cysteine are amino acids mainly found in 
foods of animal origin [1], and has roles in methylation 
reactions, protein synthesis and antioxidant production 
[2]. Dietary restriction of the amino acid methionine and 
cysteine leads to many beneficial health effects in animals 
including increased lifespan, favorable changes in body 
composition and lipogenic gene expression, increased 
insulin sensitivity, and anti-inflammatory properties [3].
In animal studies, methionine and cysteine restric-
tion reduced activity of the lipogenic enzyme stearoyl 
CoA-desaturase (SCD1) [4]. Circulating concentrations 
of cysteine are inversely associated with plasma SCD 
activity indices in large observational cohorts [5], further 
suggesting that amino acids may be involved in the reg-
ulation of the expression and/or activity of this enzyme 
in humans. SCD1 activity is also considered a target 
for supplementation with polyunsaturated fatty acids 
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plasma activity indices of SCD1 in a human intervention 
study [6]. Experimental studies with either methionine 
and cysteine restriction, or PUFA supplementation, share 
many of same beneficial effects on metabolic outcomes 
[3, 7–9].
Over the recent years, we have performed and published 
results from one 7-d and one postprandial pilot study in 
which we observed effects of a diet restricted in methionine 
and cysteine and high in PUFAs on plasma sulfur amino 
acid profile and SCD1 activity indices [10, 11]. Because 
the pilot studies were the first of its kind we also collected 
data on a wide range of potential outcomes including oral 
glucose tolerance, amino acid and total fatty acid profile as 
well as markers of glucose metabolism including pyruvate 
and lactate. The aim of the present paper was to systemati-
cally describe the response in oral glucose tolerance, amino 
acid profile, total fatty acid profile, pyruvate and lactate to 
a short-term dietary intervention with methionine and 
cysteine restriction plus enrichment of PUFA vs. a diet high 
in methionine, cysteine and saturated fatty acids (SFA).
Main text
Materials and methods
Participants, inclusion and exclusion criteria, study 
design, collection of demographic variables, anthropo-
metric measures, lifestyle and health-related data have 
been described in detail elsewhere [10]. In brief, 14 
healthy, normal-weight men (n = 4) and women (n = 10) 
were recruited through the web and social media page 
of the University of Oslo. The study was a randomized 
controlled dietary intervention in which participants 
were randomized to either a dietary intervention with 
methionine and cysteine restriction enriched in PUFA 
(Met/Cyslow + PUFA, n = 7) or with high contents of 
methionine, cysteine and SFA (Met/Cyshigh + SFA, 
n = 7). The energy content was on average 2000  kcal/d 
for women and 2500  kcal/d for men. Both diets were 
vegan-based without meat, fish, eggs, dairy products 
and certain plant-based foods. The Met/Cyslow + PUFA 
diet contained on average ~ 23.5 g total PUFA (10.9% of 
total energy [E%]) and 0.93  g methionine and cysteine 
for women, and ~ 28  g total PUFA (10.6 E%) and 1.19  g 
methionine and cysteine for men. The Met/Cyshigh + SFA 
contained 30.3 g SFA (13.5 E%) and 5.8 g methionine and 
cysteine for women, and 37.2 g SFA (13.3 E%) and 6.0 g 
methionine and cysteine for men. A full overview of the 
diet compositions and a typical daily menu can be found 
in the Additional file 1. The study protocol was approved 
by the Regional Committee for Medical Research Eth-
ics South East and was registered with the United States 
National Library of Medicine Clinical Trials registry 
(ClinicalTrials.gov Identifier: NCT02647970, January  6th 
2016). The study was in accordance with the Declaration 
of Helsinki.
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Low Met/Cys + PUFA High Met/Cys + SFA
Fig. 1 Boxplots showing glucose concentrations before (fasting) and 2 h after an oral glucose tolerance test at baseline and day 7 of the 
intervention. Met/Cys,methionine and cysteine, OGTT oral glucose tolerance test, PUFA polyunsaturated fatty acids, SFA saturated fatty acids
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Low Met/Cys + PUFA High Met/Cys + SFA
Fig. 2 Shows the amino acid concentrations for each individual (grey lines) and the mean concentrations (black lines). Gln+Ga glutamine + 
glutamate, Met/Cys methionine and cysteine, PUFA polyunsaturated fatty acids, SFA saturated fatty acids  
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The oral glucose tolerance test (OGTT) procedure 
consisted of consumption of 75 g glucose mixed in 4 dl 
of water after an overnight fast. Blood glucose concentra-
tions were measured 2 h post-OGTT.
Venous blood samples were collected at baseline, days 
3 and 7 from each participant after an overnight fast for 
the amino acids, total fatty acids, lactate and pyruvate. 
The oral glucose tolerance test was performed at base-
line and day 7. Samples were drawn in to EDTA-lined 
vacuum tubes and immediately centrifuged for five min-
utes at 4 °C. Plasma aliquots were stored at − 80 °C until 
analysis. For lactate and pyruvate, a plasma aliquot was 
immediately precipitated with 5-sulfosalicyclic acid. The 
supernatant was stored at − 80 °C until analysis.
Total plasma amino acids were measured by LC–MS/
MS using a modified version of a previously described 
method [12]. Briefly, isotopically labelled internal stand-
ards were added to plasma, followed by reduction of 
disulphides using dithioerythritol and then precipita-
tion of the plasma proteins using 5-sulfosalicyclic acid. 
LC–MS/MS of the supernatant was carried out using a 
Shimadzu LC-20ADXR Prominence LC system (Kyoto, 
Japan) coupled to a Sciex QTRAP5500 mass spectrom-
eter with a Turbo V ion source and TurboIonspray probe 
(Framingham, MA, USA). Chromatographic separation 
was achieved on a Phenomenex Kinetex Core Shell C18 
(100 × 4.6  mm, 2.6  μm) column (Torrance, CA, USA). 
Plasma concentrations of lactate and pyruvate were 
determined by LC–MS/MS. Deuterium labelled lac-
tate isotope was used as the internal standard. LC–MS/
MS of the supernatant was performed using a Shimadzu 
LC-20ADXR LC system coupled to a Sciex QTRAP5500 
mass spectrometer with Turbo V ion source and Tur-
boIonspray probe (Framingham, MA, USA). Chromato-
graphic separation of the analytes was achieved using a 
Restek Ultra AQ C18 (100 × 4.6 mm, 3 μm) column.
Plasma total fatty acid concentrations were determined 
by gas chromatography mass spectrometry (GC–MS) as 
described previously [10, 13]. Glucose concentrations were 
determined by colorimetric methods on a Cobas c702 
analyzer (Roche Diagnostics International LTd., Rotkreuz, 
Switzerland) at the Department of Medical Biochemistry 
(Oslo University Hospital Rikshospitalet, Oslo, Norway).
According to the CONSORT extension statement (Addi-
tional file  6) for pilot trials statistical hypothesis testing is 
actively discouraging because of the inherent uncertainty 
in data obtained from small samples, which are not pow-
ered to detect meaningful treatment effects [14]. In line 
with this, we present findings in a descriptive manner with 
means and median as measures of central tendency and the 
standard deviation and range as measures of dispersion in 
tables presented in the additional files. In the plots we strive 
to present individual datapoints in addition to the mean 
and/or median as a measure of central tendency. Plots were 
made in R version 4.0.2 (R for statistical computing, Austira, 
Vienna) using packages “ggplot2” and “ggthemes”.
Results
In line with the CONSORT extension statement for pilot 
trials, we did not conduct formal hypothesis tests but 
report results in a descriptive manner. A flowchart of the 
participants can be found in Additional file 2. Character-
istics of the study participants can be found in Additional 
file  3. In brief, each group consisted of 5 women and 2 
men. Median (range) age was 31 (20, 37) and 24 (21, 38) 
years in the Met/Cyslow + PUFA and Met/Cyshigh + SFA 
groups, respectively, whereas body mass index was 22.6 
(21.0, 25) and 22.3 (20.7, 26.6) kg/m2 at baseline.
An overview of the metabolite response to the inter-
vention is given in Additional file  4. The response in the 
OGTT is illustrated in Fig. 1. At baseline, median (range) 
fasting glucose concentrations were 5.0 (4.5, 5.2) and 4.8 
(4.3, 6.0) mmol/L, whereas two hours post-OGTT con-
centrations were 4.4 (2.9, 5.1) and 4.9 (3.8, 6.7) mmol/L 
in the Met/Cyslow + PUFA and Met/Cyshigh + SFA groups, 
respectively. After the 7-d intervention, fasting glucose 
concentrations were 5.0 (4.7, 5.2) and 4.8 (4.2, 5.8) mmol/L, 
whereas 2 h post-OGTT concentrations were 4.0 (3.7, 4.9) 
and 4.65 (3.9, 6) mmol/L in the Met/Cyslow + PUFA and 
Met/Cyshigh + SFA groups, respectively.
The response in plasma amino acid profile are illus-
trated in Fig. 2. The sulfur amino acid response has been 
described in a previous publication  [10]. For the other 
amino acids, plasma concentrations responded simi-
larly in both groups throughout the intervention with 
the exception of serine. Median (range) serine was 103 
(76.4, 145) µmol/L in the Met/Cyslow + PUFA group at 
baseline and 123 (74.4, 141) µmol/L at day 7. In the Met/
Cyshigh + SFA group, plasma serine was 101 (59.8, 131) at 
baseline and 96.3 (65.5, 122) µmol/L at day 7.
The response in serum total fatty acid profile is illus-
trated in Fig.  3. The fatty acid response was generally 
similar in both groups with decreases in most fatty acids 
from baseline to day 7.
The responses in plasma lactate and pyruvate are illus-
trated in Additional File 5 and were similar for both 
groups with an initial increase to day 3 before approach-
ing baseline values at day 7.
Discussion
Despite the extensive research into sulfur amino acid 
restriction in animals [3, 9, 15–19] and positive asso-
ciation with adverse health outcomes in human obser-
vational studies [5, 20, 21], this has surprisingly not been 
matched by human interventional studies with a few 
exceptions [22, 23]. In addition, the potential interaction 
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of sulfur amino acid restriction and PUFA enrichment 
has not been addressed except for previously published 
pilot studies from our group [10, 11]. In this pilot study 
we describe the response in oral glucose tolerance, 
plasma amino acids and total fatty acid profile, lactate 
and pyruvate to a short-term diet restricted in the sul-
fur amino acids methionine and cysteine and enriched 
in PUFAs. Due to the descriptive nature of the study, we 
cannot draw firm conclusions but provide data that can 
aid the planning and design of future studies with respect 
to metabolic outcomes related to amino acid, fatty acids, 
insulin sensitivity and glucose metabolism.
Of particular interest is the short-term response in 
the OGTT where the median glucose concentrations 
after the dietary intervention were lower in the Met/
Cyslow + PUFA group (5  mmol/L pre-OGTT, 4  mmol/L 
post-OGTT) than in the Met/Cyshigh + SFA group 
(4.8  mmol/L pre-OGTT, 4.65  mmol/L post-OGTT). 
We emphasize that this was a pilot study that was not 
designed to make formal comparisons, however these 
observations may warrant further investigation when 
considered in light of experimental data from animals. 
Notably, mice fed a diet low in methionine and cysteine 
exhibited lower post-OGTT glucose and insulin com-
pared with control mice fed a high-fat diet [24]. An 
intraperitoneal glucose tolerance test in mice fed a low 
cysteine diet showed decreased plasma glucose and insu-
lin responses compared to mice fed a high cysteine diet 
[25]. Detailed outlines of potential underlying mecha-
nisms can be found in the following references [3, 16, 
17, 26, 27]. Data is currently lacking from human obser-
vational and experimental studies although one study 
showed that plasma concentrations of total cysteine were 
associated with insulin resistance in Hispanic adolescents 
[28]. To further elucidate the role of the intervention diet 
on glucose metabolism and insulin resistance, long-term 
randomized dietary studies in individuals at risk for or 
with insulin resistance to address potential beneficial 
effects in prevention and/or treatment.
Due to the combination of methionine and cysteine 
restriction and PUFA enrichment, we were not able to 
distinguish potential effects of amino acid restriction 
from PUFA supplementation. However, effects of PUFA 
supplementation on glucose metabolism and insulin 
sensitivity is thought to be minimal as highlighted by a 
recent review and meta-analysis [29].
We have previously reported findings on sulfur amino 
acids and selected fatty acids [10]. The other amino acids 
generally responded similarly with the exception of ser-
ine. This is unsurprising because the amino acid compo-
sition of the two diets were identical, however, serine is 
an intermediate of methionine and cysteine metabolism 
and increased concentrations may be linked to changes 
in sulfur amino acid metabolism [2].
Changes in fatty acid profile, and pyruvate (which can 
be produced from cysteine) and lactate were generally 
similar in both groups, and it is possible that the amino 
acid and fatty acid interventions were neither intensive 
nor long enough to induce expected changes [10].
Limitations
The interpretation of these results is limited by the small 
sample size, and the short duration of the study and it is 
unlikely that meaningful effects could be detected dur-
ing such a short period of time. In addition, there were 
considerable individual variation in both baseline con-
centrations and response in the markers, especially for 
the amino acids and fatty acids, further complicating the 
interpretation. Future studies can potentially overcome 
these limitations by enrolling more subjects to increase 
power. An additional limitation, especially with respect 
to the clinical relevance of the OGTT data, is that we 
included healthy normal-weight participants and future 
studies should address these issues in subjects with, or at 
risk of developing, metabolic complications. Because this 
was a descriptive study, we are not able to draw firm con-
clusions but these data may inform and be useful in the 
planning and design of future studies.
(See figure on next page.)
Fig. 3 Shows the total fatty acid concentrations for each individual (grey lines) and the mean concentrations (black lines). Met/Cys methionine and 
cysteine, C12 lauric acid, C14 myristic acid, C16:0 palmitic acid, C16:1 palmitoleic acid, C18 stearic acid, C18:1 oleic acid, C18:2 linoleic acid, C18:3-n3 
α-linoleic acid, C18:3-n6 γ-linoleic acid, C20:3-n6 Dihomo-γ-linoleic acid, C20:4-n6 Arachidonic acid, C20:5-n3 Eicosapentanoic acid, C22:6-n3 Cervonic 
acid
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The online version contains supplementary material available at https ://doi.
org/10.1186/s1310 4-021-05463 -5.
Additional file 1: Contains a typical daily menu and the nutrient contents 
of the diets.
Additional file 2: Contains a figure of the participant flow.
Additional file 3: Contains baseline table of the study population.
Additional file 4: Contains descriptive statistics of the measured 
metabolites.
Additional file 5: Contains a figure illustrating the data on pyruvate and 
lactate.
Additional file 6: CONSORT checklist.
Abbreviations
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desaturase.
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